Longevity Supplements
Comprehensive, un-sponsored analysis of compounds studied for lifespan and healthspan extension. We review human clinical trials, bioavailability, and optimal dosing strategies.
Metabolic
NMN vs NR: The NAD+ Precursor Debate
A critical evaluation of Nicotinamide Mononucleotide and Nicotinamide Riboside. Analyzing differences in cellular uptake, pharmacokinetics, and clinical endpoints in human trials.
Read Analysis
Senolytic
Fisetin: The Mayo Clinic Protocol
Examining the rationale behind high-dose, pulsed fisetin supplementation for senescent cell clearance. Reviewing current trial data and off-label usage.
Read Analysis
Metabolic
Berberine as a Metformin Alternative
Can a plant alkaloid match the AMPK-activating effects of the most prescribed longevity drug? A look at glucose disposal rates and lipid profile impacts.
Read AnalysisOur Evaluation Criteria
- Human Trial Data: Animal models (C. elegans, mice) are insufficient. We prioritize randomized placebo-controlled human trials.
- Bioavailability: A compound is useless if it degrades before reaching systemic circulation. We assess delivery mechanisms (e.g., liposomal, enteric coating).
- Safety & Tolerability: We document known contraindications, side effects, and long-term safety profiles based on clinical data.